Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients-COVIDOUT study.
Schönlein M, Wrage V, Ghandili S, Mellinghoff SC, Brehm TT, Leypoldt LB, Utz N, Schrader RM, Alsdorf W, Börschel N, Bußmann L, Schönrock M, Perlick D, Schön G, Verpoort K, Lütgehetmann M, Schulze Zur Wiesch J, Weisel KC, Bokemeyer C, Schafhausen P, Sinn M.
Schönlein M, et al. Among authors: brehm tt.
Cancer Cell. 2022 Jun 13;40(6):581-583. doi: 10.1016/j.ccell.2022.04.016. Epub 2022 Apr 26.
Cancer Cell. 2022.
PMID: 35512712
Free PMC article.
No abstract available.